Journal article
Reach-2 Trial Design: A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Compared to Best Available Therapy in Patients with Corticosteroid-Refractory Acute Graft vs Host Disease after Allogeneic Stem Cell Transplantation
Gérard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Jeff Szer, Mohamad Mohty, Mary Laughlin, Betty Molloy, Leslie O'Sullivan-Djentuh, Robert Zeiser
Biology of Blood and Marrow Transplantation | Elsevier BV | Published : 2018